Assessing potential of psilocybin for depressive disorders
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
Expert Opinion on Investigational Drugs October 3, 2023 DOI: 10.1080/13543784.2023.2273493 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with depression, specifically those with treatment-resistant depression |
| Topics | Depression Psychedelic-assisted therapy Psilocybin |
| Keywords | Psilocybin, psychedelics Magic mushroom therapy Treatment-resistant depression trd Refractory depression |
| Citations | 10 |
| Key findings | Patients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment at this time. |
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.